TABLE 12Primary outcomes of STOP31 and STOP 235 trials

STOP, Adams (1998)31
TransfusionStandard carep-value
Primary end point
No. of strokes1 (cerebral infarction)11 (10 cerebral infarction, one intracerebral haematoma)< 0.001

Risk of stroke is 92% lower in transfusion group
STOP 2, Adams (2005)35
Continued transfusionTransfusion haltedp-value
Primary end point
No. of strokes or reversion to abnormal TCD016< 0.001
No. of strokes02
Reversion to abnormal TCD014

From: 4, Assessment of clinical effectiveness

Cover of The Clinical Effectiveness and Cost-Effectiveness of Primary Stroke Prevention in Children with Sickle Cell Disease: A Systematic Review and Economic Evaluation
The Clinical Effectiveness and Cost-Effectiveness of Primary Stroke Prevention in Children with Sickle Cell Disease: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 16.43.
Cherry MG, Greenhalgh J, Osipenko L, et al.
Southampton (UK): NIHR Journals Library; 2012 Nov.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.